Back to discover
Drug

Vonicog alfa

Approved medicine
ClassVon Willebrand factor exogenous proteinResearchOngoing clinical research
Also known as Von Willebrand Factor (Hamster) (Murine), Vonvendi, (618-THREONINE,709-ASPARTIC ACID)VON WILLEBRAND FACTOR HOMO SAPIENS (1381A>T,1472H>D VARIANT) BLOOD COAGULATION FACTOR, Recombinant human von Willebrand factor+2 more

Von Willebrand Factor (Hamster) (Murine), Vonvendi, (618-THREONINE,709-ASPARTIC ACID)VON WILLEBRAND FACTOR HOMO SAPIENS (1381A>T,1472H>D VARIANT) BLOOD COAGULATION FACTOR, Recombinant human von Willebrand factor, Von willebrand factor, recombinant, human, rVWF - recombinant human von Willebrand factor.

RxNorm1812589ChEMBLCHEMBL2107873UNII5PKM8P0G5I
2
Active clinical trials
von Willebrand factor
Primary target
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Phase 3, Prospective, Open-label, Uncontrolled, Multicenter Study on Efficacy and Safety of Prophylaxis With Vonicog Alfa (rVWF) in Children Diagnosed With Severe Von Willebrand Disease

Clinical trial2026-05-27Results expected Q2 2030 · ClinicalTrials.gov

A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF With or Without ADVATE in the Treatment and Control of Bleeding Episodes, the Efficacy and Safety of rVWF in Elective and Emergency Surgeries, and the Pharmacokinetics (PK) of rVWF in Children Diagnosed With Severe Von Willebrand Disease

Clinical trial2026-04-17Completed · ClinicalTrials.gov

A Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in the Treatment of Bleeding Episodes in Chinese Subjects Diagnosed With Von Willebrand Disease

Clinical trial2026-01-08Results expected Q4 2027 · ClinicalTrials.gov

Approval: Veyvondi (EMA)

Regulatory2018-08-31EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Vonicog alfa
Aliases & brands
Von Willebrand Factor (Hamster) (Murine)Vonvendi(618-THREONINE,709-ASPARTIC ACID)VON WILLEBRAND FACTOR HOMO SAPIENS (1381A>T,1472H>D VARIANT) BLOOD COAGULATION FACTORRecombinant human von Willebrand factorVon willebrand factor, recombinant, humanrVWF - recombinant human von Willebrand factor
RxNorm CUI
1812589
ChEMBL ID
CHEMBL2107873
UNII
5PKM8P0G5I
Primary mechanism
Von Willebrand factor exogenous protein
Regulatory jurisdictions
ema

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

von Willebrand factor
VWF · P04275
EXOGENOUS PROTEINvon Willebrand factor exogenous protein

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2018-08-31
Latest approval
2018-08-31
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2018-08-31Approval
Approval: Veyvondi (EMA)
Indication: Prevention and treatment of haemorrhage or surgical bleeding in adults (age 18 years and older) with von Willebrand disease (VWD), when desmopressin (DDAVP) treatment alone is… Show full indication

Prevention and treatment of haemorrhage or surgical bleeding in adults (age 18 years and older) with von Willebrand disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or contraindicated. Veyvondi should not be used in the treatment of Haemophilia A.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

3 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
3
registered trials across all phases
LATEST COMPLETION 2026
2
Active studies
2
Recruiting
3
Late-stage (III+)
1
Completed
PHASE DISTRIBUTIONn = 3
Phase 33

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Phase 3, Prospective, Open-label, Uncontrolled, Multicenter Study on Efficacy and Safety of Prophylaxis With Vonicog Alfa (rVWF) in Children Diagnosed With Severe Von Willebrand Disease

RecruitingPH IIITakedan=242030

A Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in the Treatment of Bleeding Episodes in Chinese Subjects Diagnosed With Von Willebrand Disease

RecruitingPH IIITakedan=202027

A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF With or Without ADVATE in the Treatment and Control of Bleeding Episodes, the Efficacy and Safety of rVWF in Elective and Emergency Surgeries, and the Pharmacokinetics (PK) of rVWF in Children Diagnosed With Severe Von Willebrand Disease

CompletedPH IIIBaxalta now part of Shiren=472026
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.